Camelot Portfolios’s CapForce IBD 50 ETF FFTY Stock Holding History

Camelot Portfolios’s Portfolio FFTY Stock Details FFTY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-175	Closed	-$6.09K	–	310
2025 Q4	$6.09K	Buy	+175	New	+$6.45K	﹤0.01%	467

Other funds holding FFTY

CPA

Clear Point Advisors Melville, New York $129M AUM 12.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CFP

Comprehensive Financial Planning East Petersburg, Pennsylvania $144M AUM 25.61% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DSCM

Del-Sette Capital Management Schenectady, New York $167M AUM 38.06% 1-Year Est. Return

Camelot Portfolios's FFTY Position: Q1 2026 in Review

Camelot Portfolios sold out of CapForce IBD 50 ETF (FFTY) in Q1 2026, closing a stake of 175 shares — an estimated $6.09K sold.

Camelot Portfolios first reported a position in FFTY in Q4 2025 and held it in 1 quarter. The position peaked at $6.09K in Q4 2025. 39 funds tracked by Wall St. Rank hold FFTY as of Q1 2026.

Camelot Portfolios reported no remaining CapForce IBD 50 ETF position as of Q1 2026 after selling out during the quarter.
Camelot Portfolios sold 175 CapForce IBD 50 ETF shares in Q1 2026, an estimated $6.09K.
Camelot Portfolios first reported a position in CapForce IBD 50 ETF in Q4 2025 and held it in 1 quarter.
Camelot Portfolios's CapForce IBD 50 ETF position peaked at $6.09K in Q4 2025.
39 funds tracked by Wall St. Rank held CapForce IBD 50 ETF as of Q1 2026.

Based on Camelot Portfolios's 13F filing for Q1 2026, filed 8 May 2026.